Will Testing for Tumor Mutational Burden Bring the Same Challenges as Testing for PD-L1?

被引:0
|
作者
Gupta V. [1 ]
Ramirez M.C. [1 ]
Schauser L. [1 ]
机构
[1] QIAGEN, India
来源
关键词
3;
D O I
10.1089/gen.39.06.19
中图分类号
学科分类号
摘要
[No abstract available]
引用
收藏
页码:56 / 57
页数:1
相关论文
共 50 条
  • [21] Tumor mutational burden (TMB) and PD-L1 expression as predictors of response to immunotherapy (IO) in NSCLC.
    Castellanos, Emily
    Snider, Jeremy
    Ali, Siraj Mahamed
    Backenroth, Daniel
    Albacker, Lee A.
    Murugesan, Karthikeyan
    Li, Gerald
    Frampton, Garrett M.
    Alexander, Brian Michael
    Carson, Kenneth Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [22] FREQUENT HIGH TUMOR MUTATIONAL BURDEN (TMB) AND PD-L1 EXPRESSION IN PRIMARY CNS LYMPHOMA (PCNSL)
    Sumrall, Ashley
    Phuphanich, Surasak
    Spetzler, David
    Gatalica, Zoran
    Xiu, Joanne
    Provenzano, Aaron
    Brenner, Andrew J.
    Subramaniam, Deepa
    Pandey, Majari
    Heimberger, Amy
    Kesari, Santosh
    Korn, W. Michael
    Mittal, Sandeep
    NEURO-ONCOLOGY, 2018, 20 : 240 - 241
  • [23] PD-L1 expression, tumor mutational burden, and microsatellite instability status in 746 pancreas ductal adenocarcinomas
    Hemmerich, Amanda
    Edgerly, Claire I.
    Duncan, Daniel
    Huang, Richard
    Danziger, Natalie
    Frampton, Garrett M.
    Elvin, Julia Andrea
    Vergilio, Jo-Anne
    Killian, Jonathan Keith
    Lin, Douglas I.
    Williams, Erik
    Ali, Siraj Mahamed
    Reddy, Prasanth
    Miller, Vincent A.
    Owens, Clarence
    Brown, Charlotte
    Alexander, Brian M.
    Ross, Jeffrey S.
    Severson, Eric Allan
    Ramkissoon, Shakti H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [24] Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers
    Duruisseaux, Michael
    Rouquette, Isabelle
    Adam, Julien
    Cortot, Alexis
    Cazes, Aurelie
    Gibault, Laure
    Damotte, Diane
    Lantuejoul, Sylvie
    ANNALES DE PATHOLOGIE, 2017, 37 (01) : 61 - 78
  • [25] Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden
    Gong, Jun
    Patel, Sandip
    Adashek, Jacob J.
    Frishberg, David
    Guan, Michelle
    Placencio-Hickok, Veronica R.
    Gangi, Alexandra
    Gresham, Gillian
    Tuli, Richard
    Chae, Young K.
    Kurzrock, Razelle
    Hendifar, Andrew E.
    JCO PRECISION ONCOLOGY, 2020, 4 : 514 - 519
  • [26] Challenges of PD-L1 testing in non-small cell lung cancer and beyond
    Wang, Minyu
    Wang, Sen
    Trapani, Joseph A.
    Neeson, Paul J.
    JOURNAL OF THORACIC DISEASE, 2020, 12 (08) : 4541 - 4548
  • [27] Profiling of Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), and PD1/PD-L1 Immunohistochemistry (IHC) in Gynecological Tumors
    Elvin, Julia A.
    Goldberg, Michael E.
    Gay, Laurie M.
    Liao, John
    Santin, Alessandro D.
    Suh, James
    Vergilio, Jo-Anne
    Ramkissoon, Shakti H.
    Fabrizio, David
    Frampton, Garrett
    Stephens, Philip
    Ross, Jeffrey
    LABORATORY INVESTIGATION, 2017, 97 : 283A - 283A
  • [28] Profiling of Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), and PD1/PD-L1 Immunohistochemistry (IHC) in Gynecological Tumors
    Elvin, Julia A.
    Goldberg, Michael E.
    Gay, Laurie M.
    Liao, John
    Santin, Alessandro D.
    Suh, James
    Vergilio, Jo-Anne
    Ramkissoon, Shakti H.
    Fabrizio, David
    Frampton, Garrett
    Stephens, Philip
    Ross, Jeffrey
    MODERN PATHOLOGY, 2017, 30 : 283A - 283A
  • [29] PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
    Katerina Ancevski Hunter
    Mark A. Socinski
    Liza C. Villaruz
    Molecular Diagnosis & Therapy, 2018, 22 : 1 - 10
  • [30] PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
    Hunter, Katerina Ancevski
    Socinski, Mark A.
    Villaruz, Liza C.
    MOLECULAR DIAGNOSIS & THERAPY, 2018, 22 (01) : 1 - 10